Protective Effect of Piper Sarmentosum against Dexamethasone-Induced Hyperlipidemia in Rats

Fadze, Noor Fazilah Md; Ugusman, Azizah; Aminuddin, Amilia

doi:10.1016/j.ijcard.2018.11.080

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ali et al [124] also reported similar results in ovariectomyinduced obese rats treated with the aqueous leaf extract of PS (125 mg/kg/day for 5 months). The aqueous leaf extract of PS (500 mg/kg/day for 28 days) also reduced serum TC, TG, and LDL, but did not change the HDL levels [125]. Additionally, 3hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR) activity was reduced by PS (the methanolic leaf extract 125 mg/kg/day for 4 weeks) in fructose-induced MetS rats and ovariectomy-induced obese rats (the aqueous leaf extract, 125 mg/kg/day for 5 months).…”

Section: Effect Of Ps On Dyslipidaemia and Its Complicationsmentioning

confidence: 90%

Effects of Piper sarmentosum on Metabolic Syndrome and Its Related Complications: A Review of Preclinical Evidence

2021

View full text Add to dashboard Cite

Piper sarmentosum (PS) is a traditional medicinal herb used by South East Asians. It demonstrates promising properties against various non-communicable diseases and infectious agents due to its antioxidant and anti-inflammatory properties. Given that oxidative stress and inflammation are involved in developing and exacerbating metabolic syndrome (MetS) and its principal components (central obesity, hyperglycaemia, hypertension, and dyslipidaemia), PS could manage MetS and its complications. This review summarises the available literature on the effects of PS on principal components of MetS and their complications. The accumulated evidence suggests that PS prevented adiposity, hyperglycaemia, hypertension, and dyslipidaemia in preclinical studies mainly through its antioxidant and anti-inflammatory properties. It also protected against MetS-associated cardiovascular complications. This review has identified research gaps in this field and suggested future studies to guide interested researchers to explore further or affirm the therapeutic potential of PS. One of the most significant challenges to the medical use of PS is the absence of randomised controlled trials in humans. This study gap must be bridged before PS supplementation could be used to manage MetS in humans.

show abstract

Section: Effect Of Ps On Dyslipidaemia and Its Complicationsmentioning

confidence: 90%